FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileCogent Biosciences, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
COGT
Cogent Biosciences, Inc. Stock AnalysisComprehensive stock analysis for Cogent Biosciences, Inc. (COGT) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisCOGT
COGT
Cogent Biosciences, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
COGT
  1. Home
  2. Stocks
  3. Cogent Biosciences, Inc.

Cogent Biosciences, Inc.

🇺🇸COGT•NASDAQ

Cogent Biosciences, Inc.

🇺🇸COGT•NASDAQ
Market cap
$4.65B

Your view on COGT

Mkt Cap
$4.65B
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Cogent Biosciences, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Andrew R. Robbins
Headquarters
200 Cambridge Park Drive, Waltham, MA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Andrew R. Robbins
Headquarters
200 Cambridge Park Drive, Waltham, MA, US
Description

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases.

Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.

It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Cogent Biosciences, Inc.. Starting points for Cogent Biosciences, Inc.: EPS -$2.35, beta 0.34 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Cogent Biosciences, Inc.. Trailing twelve-month EPS for Cogent Biosciences, Inc. stands at -$2.35. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 22, 2026
Analysts' target$50.00average of 7 firms, last 12 months
Current price—

Buy

Targets, low to high

$50.00

Low $35.00

Middle $52.00

High $60.00

Analyst ratings

6 firms, last 12 months
  • Strong Buy0
  • Buy5
  • Hold1
  • Sell0
  • Strong Sell0
More →

Earnings per share estimates

Per shareThis quarterDec 2020Next quarterMar 2025This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate−$0.51−$0.59−$2.33−$1.20
Lowest estimate−$0.51−$0.68−$2.45−$1.74
Highest estimate−$0.51−$0.49−$2.23−$0.42
Number of analysts9579
A year ago——−$2.04—
Growth vs a year ago——−14.3%—

Revenue estimates

TotalThis quarterDec 2020Next quarterMar 2025This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate$50000.00$179933.00$5.44M$287.93M
Lowest estimate$50000.00$50761.00$2.15M$141.39M
Highest estimate$50000.00$267538.00$7.85M$377.45M
Number of analysts5589
A year ago——$0.00—
Growth vs a year ago————
Recent rating and target changes (15)

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Cogent Biosciences, Inc.. Cogent Biosciences, Inc. has reported as a listed company since 2018. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold COGT20 companies · 8 funds
Compare COGT with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustryMkt cap
AVBPArriVent BioPharma, Inc. Common StockHealthcareBiotechnology$544.1M
IDYAIDEAYA Biosciences, Inc.HealthcareBiotechnology$2.5B
INCYIncyte CorporationHealthcareBiotechnology$23.4B
KURAKura Oncology, Inc.HealthcareBiotechnology$634.9M
MAZEMaze Therapeutics, Inc.HealthcareBiotechnology$1.7B
NRIXNurix Therapeutics, Inc.HealthcareBiotechnology$1.4B
RCUSArcus Biosciences, Inc.HealthcareBiotechnology$2.2B
SNDXSyndax Pharmaceuticals, Inc.HealthcareBiotechnology$785.0M
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
FRX.TOFennec Pharmaceuticals Inc.HealthcareTSX$681.0M
FTHFaeth Therapeutics, Inc.HealthcareNASDAQ$203.1M
FTREFortrea Holdings Inc.HealthcareNASDAQ$1.8B
FULCFulcrum Therapeutics, Inc.HealthcareNASDAQ$281.8M
GALTGalectin Therapeutics Inc.HealthcareNASDAQ$177.2M
GANXGain Therapeutics, Inc.HealthcareNASDAQ$42.6M
GBIMGlobeImmune, Inc.HealthcareOTC$575
GBLXGB Sciences, Inc.HealthcareOTC$122,121
GDTCCytoMed Therapeutics LimitedHealthcareNASDAQ$8.9M
GENBGenerate Biomedicines, Inc.HealthcareNASDAQ$1.2B
GENSFGenus plcHealthcareOTC$2.5B
GERNGeron CorporationHealthcareNASDAQ$560.9M
ETFs holding Cogent Biosciences, Inc.
TickerFundFund assets% of the fund
IWMiShares Russell 2000 ETF$76.6B in assets0.16%
VTIVanguard Total Stock Market ETF$689.2B in assets0.01%
XBIState Street SPDR S&P Biotech ETF$10.0B in assets1.15%
VBVanguard Small-Cap ETF$76.9B in assets0.06%
LFSCF/M Emerald Life Sciences Innovation ETF$125M in assets6.14%
CANCTema Oncology ETF$215M in assets4.38%
VTWGVanguard Russell 2000 Growth ETF$1.4B in assets0.34%
IBBiShares Biotechnology ETF$11.1B in assets0.31%

Largest holders first, then the funds most concentrated in COGT.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Cogent Biosciences, Inc., and how their positions are changing. At a $4.65B market value, institutional positions materially move Cogent Biosciences, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Cogent Biosciences, Inc. executives and directors. Shares of Cogent Biosciences, Inc. have traded between $3.72 and $36.29 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

House Trading

U.S. Representative disclosures filed under the STOCK Act.

About this section

U.S. House of Representatives disclosures naming Cogent Biosciences, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Cogent Biosciences, Inc.. Coverage tracks Cogent Biosciences, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Cogent Biosciences, Inc.

COGT AnalysisWeak
Past
1
Growth
2
Health
3
Profit
1
Value
1